MindWalk (HYFT) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NextCure (NXTC) has outperformed MindWalk (HYFT) over the past year, losing 38.6% versus a loss of 59.0%. Over five years, HYFT leads with a -89.3% price change compared with -91.1% for NXTC. MindWalk is the larger company by market cap ($32.6 million vs $29.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYFT | NXTC |
|---|---|---|
| Share price | $0.6844 | $6.45 |
| Market cap | $32.56M | $29.53M |
| 1-day change | -14.27% | -4.87% |
| YTD return | -62.40% | -54.55% |
| 1-year return | -59.02% | -38.63% |
| 5-year return | -89.34% | -91.07% |
| EPS (TTM) | $-0.26 | $-6.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-55.84M |
| 52-week high | $2.99 | $15.74 |
| 52-week low | $0.64 | $1.55 |
| Distance from 52-week high | -77.11% | -59.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +532.67% | +210.08% |
| Average volume | 257.86K | 79.46K |
| Shares outstanding | 47.57M | 4.58M |
| Employees | 74 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed HYFT by 20.4 percentage points over the past year.
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
HYFT vs NXTC FAQ
Which is bigger, MindWalk or NextCure?
MindWalk (HYFT) is larger, with a market capitalization of $32.56M compared with $29.53M for NextCure (NXTC).
Which stock has performed better over the past year, HYFT or NXTC?
NXTC returned -38.63% over the past 12 months, compared with -59.02% for HYFT (price return, excluding dividends). Past performance does not predict future results.
Are MindWalk and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.